+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Empagliflozin"

Type 2 Diabetes Market Report 2025 - Product Thumbnail Image

Type 2 Diabetes Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Diabetic Gastroparesis Treatment Market Report 2025 - Product Thumbnail Image

Diabetic Gastroparesis Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Empagliflozin, Dapagliflozin and Canagliflozin Market Report 2024 - Product Thumbnail Image

Empagliflozin, Dapagliflozin and Canagliflozin Market Report 2024

  • Report
  • September 2024
  • 175 Pages
  • Global
From
From
Type 2 Diabetes Pipeline Analysis Report - Product Thumbnail Image

Type 2 Diabetes Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
From
Diabetes Care Drugs Market - Forecasts from 2022 to 2027 - Product Thumbnail Image

Diabetes Care Drugs Market - Forecasts from 2022 to 2027

  • Report
  • October 2022
  • 138 Pages
  • Global
From
From
Empagliflozin Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

Empagliflozin Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
From
Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
JARDIANCE Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

JARDIANCE Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
Insulin Resistance - Pipeline Insight, 2024 - Product Thumbnail Image

Insulin Resistance - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Loading Indicator

Empagliflozin is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to lower blood sugar levels. Empagliflozin is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Empagliflozin is marketed by several pharmaceutical companies, including Boehringer Ingelheim, Eli Lilly, and Merck. It is available in tablet form and is taken once daily. It is also available in combination with other diabetes medications, such as metformin and linagliptin. Show Less Read more